1. McCarty MA, Garton RA, Jorizzo JL: Complex aphthosis and Behçet's disease. Dermatol Clin 21:41, 2003
2. Suzuki Kurokawa M, Suzuki N: Behçet's disease. Clin Exp Med 4:10, 2004
3. Zouboulis CC, Keitel W: A Historical review of early descriptions of Adamantiades-Behçet's disease. J Invest Dermatol 119:201, 2002
4. Zouboulis CC: Epidemiology of Adamantiades-Behçet's disease. In: Immunology of Behçet's Disease, edited by M Zierhut, S Ohno. Lisse, Swets & Zeitlinger, 2003, p. 1
5. Azizlerli G et al: Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol 42:803, 2003
6. Altenburg A et al: Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany—Current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges 4:49, 2006
7. Zouboulis CC, May T: Pathogenesis of Adamantiades-Behçet's disease. Med Microbiol Immunol 192:149, 2003
8. Hirohata S, Kikutchi H: Behçet's disease. Arthritis Res Ther 5:139, 2003
9. de Menthon M et al: HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 61:1287, 2009
10. Zouboulis CC, Turnbull JR, Martus P: Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades-Behçet's disease. Adv Exp Med Biol 528:123, 2003
11. Fietta P: Behçet's disease: Familial clustering and immunogenetics. Clin Exp Rheumatol 23: (Suppl. 38):S96, 2005
12. Durrani K, Papaliodis GN: The genetics of Adamantiades-Behcet's disease. Semin Ophthalmol 23:73, 2008
13. Zierhut M et al: Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 60: 1903,2003
14. Remmers EF et al: Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 42: 698, 2010
15. Papoutsis N et al: HLA-antigens and their importance as prognostic-marker in Adamantiades-Behçet's disease (ABD)—Is HLA-Bw4 a new prognostic marker? Abstracts of the 14th International Conference on Behçet's Disease, London, UK, 2010, p. 163
16. Escudier M, Bagan J, Scully C: Behçet's disease (Adamantiades syndrome). Oral Dis 12:78, 2006
17. Mizuki N et al: Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet. 42:703, 2010
18. Lee EB et al: Haplotype association of IL-8 gene with Behcet's disease. Tissue Antigens 69:128, 2007
19. Jiang Z et al: IL-23R gene confers susceptibility to Behcet's disease in a Chinese Han population. Ann Rheum Dis 69:1325, 2010
20. Kaneko F et al: The role of infectious agents in the pathogenesis of Behçet's disease. Adv Exp Med Biol 528:181, 2003
21. Zouboulis CC, Turnbull JR, Mühlradt PF: High seroprevalence of anti-Mycoplasma fermentans antibodies in patients with malignant aphthosis. J Invest Dermatol 121:211, 2003
22. Neves FS et al: Neutrophil hyperchemotaxis in Behçet's disease: A possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol 28:1403, 2009
23. Gül A: Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4:81, 2005
24. Yanagihori H et al: Role of IL-12B promoter polymorphism in Adamantiades-Behçet's disease susceptibility: An involvement of Th1 immunoreactivity against Streptococcus sangunis antigen. J Invest Dermatol 126:1534, 2006
25. Freysdottir J et al: Diversity of gd T cells in patients with Behçet's disease is indicative of polyclonal activation. Oral Dis 12:271, 2006
26. Mahesh SP et al: Alpha tropomyosin as a self-antigen in patients with Behçet's disease. Clin Exp Immunol 140:368, 2005
27. Lu Y et al: Identification of kinectin as a novel Behçet's disease autoantigen. Arthritis Res Ther 7:R1133, 2005
28. Direskeneli H, Saruhan-Direskeneli G: The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol 21:S44, 2003
29. Birtas-Atesoglu E et al: Serum levels of free heat shock protein 70 and anti-HSP70 are elevated in Behçet's disease. Clin Exp Rheumatol 26:(Suppl. 50):S96, 2008
30. Katsantonis J et al: Adamantiades-Behçet's disease: Serum IL-8 is a more reliable marker for disease activity than c-reactive protein and erythrocyte sedimentation rate. Dermatology 201:37, 2000
31. Durmazlar SP et al: Significance of serum interleukin-8 levels in patients with Behcet's disease: High levels may indicate vascular involvement. Int J Dermatol 48:259, 2009
32. Polat M et al: Classifying patients with Behçet's disease for disease severity, using a discriminating analysis method. Clin Exp Dermatol 34:151, 2009
33. Chi W et al: Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 49:3058, 2008
34. Habibagahi Z, Habibagahi M, Heidari M: Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet's disease. Mod Rheumatol 20:154, 2010
35. Kalayciyan A, Zouboulis CC: An update on Behçet's disease. J Eur Acad Dermatol Venereol 21:1, 2007
36. Lee KH et al: Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease. Arthritis Rheum 48:2025, 2003
37. International Study Group for Behçet's Disease: Criteria for diagnosis of Behçet's disease. Lancet 335:1078, 1990
38. Kaneko F et al: Behçet's disease and diseases for its differential diagnosis in dermatology. An annual report of the Behçet's Disease Research Committee of Japan, 1999, p. 128
39. Schirmer M et al: Evaluation and revision of the International Criteria for Behçet's Disease (ICBD). Abstracts of the 14th International Conference on Behçet's Disease, London, UK, 2010, p. 145
40. Davatchi F et al: Validation of the International Criteria for Behçet's disease (ICBD) in Iran. Int J Rheum Dis 13:55, 2010
41. Oh SH et al: Comparison of the clinical features of recurrent aphthous stomatitis and Behçet's disease. Clin Exp Dermatol 34:e208, 2009
42. Jorizzo JL et al: Mucocutaneous criteria for the diagnosis of Behçet's disease: An analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 32:968, 1995
43. Krause L: Morbus Adamantiades-Behcet. Ophthalmologe 102:329, 2005
44. Rogers RS 3rd: Pseudo-Behçet's disease. Dermatol Clin 21:49, 2003
45. Zouboulis CC et al: Current epidemiological data from the German Registry of Adamantiades-Behçet's disease. Adv Exp Med Biol 528:43, 2003
46. Sakamoto M et al: Prognostic factors of vision in patients with Behçet disease. Ophthalmology 102:317, 1995
47. Coskun B, Öztürk P, Saral Y: Are erythema nodosum-like lesions and superficial thrombophlebitis prodromal in terms of visceral involvement in Behçet's disease? Int J Clin Pract 59:69, 2005
48. Zouboulis CC: Adamantiades-Behçet's disease. In: European Handbook of Dermatological Treatments, edited by AD Katsambas, TM Lotti, 2nd edition. Berlin Heidelberg, Springer, 2003, p16
49. Alpsoy E: Behçet's disease: Treatment of mucocutaneous lesions. Clin Exp Rheumatol 23:532, 2005
50. Lee JH, Jung JY, Bang D: The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: Comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease. J Eur Acad Dermatol Venereol 22:590, 2008
51. Atmaca LS, Yalçindaĝ FN, Ozdemir O: Intravitreal
triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease.
Graefes Arch Clin Exp Ophthalmol 245:451, 2007
52. Tuncer S et al: Results of intravitreal
triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease.
J Ocul Pharmacol Ther 23:395, 2007
53. Pipitone N et al: New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol 18:3, 2006
54. Hatemi G et al: Management of Behçet disease: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 68:1528, 2009
55. Mat C et al: A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 45:348, 2006
56. Matsuda T et al: Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: A randomised, double-blind, placebo-controlled study. Drugs R D 4:19, 2003
57. Davatchi F et al:
Colchicine versus placebo in Behçet's disease: Randomized, double-blind, controlled crossover trial.
Mod Rheumatol 19:542, 2009
58. Yurdakul S et al: A double-blind trial of
colchicine in Behçet's syndrome.
Arthritis Rheum 44:2686, 2001
59. Aktulga E et al: A double blind study of
colchicine in Behcet's disease.
Haematologica 65:399, 1980
60. Sharquie KE, Najim RA, Abu-Raghif AR:
Dapsone in Behçet's disease: A double-blind, placebo-controlled, cross-over study.
J Dermatol 29:267, 2002
61. Yazici H et al: A controlled trial of
azathioprine in Behçet's disease.
N Engl J Med 322:281, 1990
62. Alpsoy E et al: Interferon alfa-2a in the treatment of Behçet's disease: A randomized placebo-controlled and double-blind study. Arch Dermatol 138:467, 2002
63. Kiliç H et al: Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome. Rheumatology (Oxford) 48:1388, 2009
64. Hamuryudan V et al:
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med 128:443, 1998
65. Masuda K et al: Double-masked trial of cyclosporin versus
colchicine and long-term open study of cyclosporin in Behçet's disease.
Lancet 1(8647):1093, 1989
66. Ozyazgan Y et al: Low dose cyclosporin A versus pulsed
cyclophosphamide in Behcet's syndrome: a single masked trial.
Br J Ophthalmol 76:241, 1992
67. BenEzra D et al: Evaluation of conventional therapy versus
cyclosporine A in Behcet's syndrome.
Transplant Proc 20: (Suppl. 4):136, 1988
68. Melikoglu M et al: Short-term trial of
etanercept in Behçet's disease: A double blind, placebo controlled study.
J Rheumatol 32:98, 2005
69. Davies UM, Palmer RG, Denman AM: Treatment with
acyclovir does not affect orogenital ulcers in Behcet's syndrome: A randomized double-blind trial.
Br J Rheumatol 27:300, 1988
70. Moral F et al: Inefficacy of azapropazone in the acute arthritis of Behcet's syndrome: A randomized, double blind, placebo controlled study. Clin Exp Rheumatol 13:493, 1995
71. Sfikakis PP et al: Anti-TNF therapy in the management of Behçet's disease: Review and basis for recommendations. Rheumatology (Oxford) 46:736, 2007
72. Nanke Y et al: Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease: An open-label, single-centre study. Drugs R D 9:455, 2008
73. Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behçet's disease with systemic interferon alfa. Arch Dermatol 134:1010, 1998
74. Krause L et al: Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a. J Rheumatol 35:896, 2008
75. Guillaume-Czitrom S et al: Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 46:1570, 2007
76. Zouboulis CC: Morbus Adamantiades-Behçet. In: Ciclosporin in der Dermatologie, edited by U Mrowietz. Stuttgart, Thieme, 2003, p. 38
77. Niccoli L et al: Long-term efficacy of
infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Rheumatology (Oxford) 46:1161, 2007
78. Tognon S, Graziani G, Marcolongo R: Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: Advantages and controversial aspects. Ann N Y Acad Sci 1110:474, 2007
79. Pipitone N A et al:
Infliximab for the treatment of Neuro-Behçet's disease: A case series and review of the literature.
Arthritis Rheum 59:285, 2008
80. Naganuma M et al: Efficacy of
infliximab for induction and maintenance of remission in intestinal Behçet's disease.
Inflamm Bowel Dis 14:1259, 2008
81. Bawazeer A, Raffa LH: Clinical experience with
adalimumab in the treatment of ocular Behçet disease.
Ocul Immunol Inflamm 18:226, 2010
82. Yasui K et al:
Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease.
Inflamm Bowel Dis 14:396, 2008
83. Davies UM, Palmer RG, Denman AM: Treatment with
acyclovir does not affect orogenital ulcers in Behcet's syndrome: A randomized double-blind trial.
Br J Rheumatol 27:300, 1998